<DOC>
	<DOCNO>NCT00170625</DOCNO>
	<brief_summary>Compatibility topotecan therapy combination carboplatin .</brief_summary>
	<brief_title>Therapy With Topotecan Carboplatin Patients With Relapsed Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Age &gt; = 18 year patient ovarian cancer primary therapy bone marrow function leukocytes &gt; = 4,0 x 109/ l , platelet &gt; = 100 109/l , hemoglobin &gt; = 9 g/dl renal function creatinin &lt; = 1,5 mg % creatinin clearance &gt; = 60 ml/min liver function bilirubin &lt; = 2,0 mg/dl , SGOT , SGPT AP within 3 fold reference laboratory 's normal range ECOG &lt; = 2 Intention regular followup visit duration study write informed consent know hypersensitivity topotecan isomeraseIinhibitor medication include study protocol ECOG &gt; 2 patient radiotherapy within last 4 week</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>platin-resistant</keyword>
</DOC>